Dongwha Pharm Applies for Phase 2 Clinical Trial of COVID-19 Treatment
[Asia Economy Reporter Cho Hyun-ui] Dong Wha Pharm announced on the 19th that it has submitted an Investigational New Drug (IND) application for the Phase 2 clinical trial of the novel coronavirus disease (COVID-19) treatment 'DW2008S' to the Ministry of Food and Drug Safety. DW2008 is a new drug being developed by Dong Wha Pharm as an asthma treatment.
Dong Wha Pharm stated that antiviral efficacy was confirmed in animal tests using ferrets (a type of weasel) conducted at Chungbuk National University for DW2008S.
The research team measured the viral titer in the nasal wash fluid of ferrets infected with COVID-19. The DW2008S treatment group showed antiviral effects from day 2, the early stage of infection, compared to the control group, and continuous effects were observed throughout the test period.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Lee Masae, head of research at Dong Wha Pharm, explained, "It took a long time to obtain the animal efficacy test results, but as expected, antiviral efficacy was positively observed in DW2008S."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
